Spectrum Pharmaceuticals terminates credit facility upon issuing notes

By Marisa Wong

Madison, Wis., Dec. 23 - Spectrum Pharmaceuticals Inc. terminated its credit agreement date Sept. 5, 2012 on Dec. 20 in connection with an issuance of convertible notes, according to an 8-K filing with the Securities and Exchange Commission.

On Dec. 17 Spectrum priced $100 million of five-year convertibles at par to yield 2.75% with an initial conversion premium of 27.5%, and on Dec. 20 the underwriters exercised the deal's $20 million greenshoe in full.

All commitments to extend further credit under the credit agreement were terminated and all liens securing obligations under the facility were released.

At the time of termination, the company did not have any outstanding borrowings, the filing noted.

Bank of America, NA was the administrative agent for the credit agreement.

Henderson, Nev.-based Spectrum is a biopharmaceutical company that develops and acquires drug products primarily in the in the area of hematology and oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.